A Phase 3 interventional study of Minocycline in Treatment Resistant Depression, sponsored by Centre for Addiction and Mental Health. Completed at 1 site in Canada. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Centre for Addiction and Mental Health · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Depressive Disorder, Treatment-Resistant by Centre for Addiction and Mental Health — 4 open to participants now, 5 under way, none of them phase 3. Depressive Disorder, Treatment-Resistant · Centre for Addiction and Mental Health.
Among the 15 studies in Depressive Disorder, Treatment-Resistant by Centre for Addiction and Mental Health, this one is the 5th largest by enrollment, is the only one that started in 2020, is the only one in phase 3, and was the 5th registered.
448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →4 of the 15 studies in Depressive Disorder, Treatment-Resistant by Centre for Addiction and Mental Health are open now, in 1 country. Recruiting first, the newest first:
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–70
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 60+
By country, each count listing its studies:
Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is above the median of 59 across 372 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 40 across the 15 interventional studies. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Centre for Addiction and Mental Health is the lead sponsor of 339 studies on the registry; 51 are open to participants now.
3 of the studies in Depressive Disorder, Treatment-Resistant by Centre for Addiction and Mental Health that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06731621Centre for Addiction and Mental HealthPsilocybin for Treatment-Resistant Depression in Autism | 2027-01 |
| NCT06518720Centre for Addiction and Mental HealthTreatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND) | 2027-03 |
| NCT06512220Centre for Addiction and Mental HealthImaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST) | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Depressive Disorder, Treatment-Resistant by Centre for Addiction and Mental Health, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Major depressive disorder (MDD) is a leading cause of disability worldwide. Up to 50% of patients experience treatment resistant depression (TRD), which accounts for a vast majority of disease burden. Current medications for TRD have limited efficacy and can be associated with intolerable side effects. Therefore, there is a need for finding new treatment targets. Accumulating evidence suggests some patients with MDD including those with TRD, display brain inflammation. Thus, patients with TRD may benefit from medications that can reduce this inflammation. Minocycline is an antibiotic which can cross the blood-brain barrier and has effects on several systems implicated in depression. The principal investigator led the first pilot study of minocycline as an add-on treatment in TRD demonstrating that it led to a significant reduction in depressive symptoms compared to placebo and these findings require replication in a larger sample to confirm the efficacy and tolerability of this treatment approach.
This study is a 12 week, double-blind, placebo-controlled trial of minocycline as add-on treatment for patients suffering from a major depressive episode who have failed to respond to antidepressant treatment, confirmed by the Structured Clinical Interview for DSM-5 (SCID-5) and the Antidepressant Treatment History Form (ATHF) at screening. After screening and randomization to the two parallel arms of the trial, 50 patients will receive minocycline added to treatment as usual (TAU) and 50 patients will receive placebo added to TAU. Clinical assessment will include the Hamilton Depression Rating Scale (HRSD-17), Clinical Global Impression scale (CGI), World Health Organization Quality of Life Short Form (WHOQOL-BREF), and Generalized Anxiety Disorder scale (GAD-7), administered at each study visit (baseline, week 2, 6, and 12). Side effects checklists will be undertaken at each visit. Minocycline will be started at 100 mg once daily and will be increased to 100 mg twice daily at two weeks. Secondary outcomes include inflammatory biomarkers measured at baseline, weeks 6 and 12.
This trial will provide further evidence of minocycline's efficacy and acceptability as a treatment option for patients with TRD and provide insights into its mechanism of action.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Minocycline will start at an oral dose of 100mg daily and will be increased after one week to 100mg twice daily.
Drug: Minocycline
Placebo capsules will start at one capsule daily, and will be increased after one week to one capsule twice daily
Drug: Minocycline
Participants will be randomized to receive either Minocycline or placebo added to standard oral antidepressants.
Also known as: Apo-Minocycline
Depressive symptoms
Changes from baseline to week 12 on the 17-item Hamilton Rating Scale for Depression (HRSD-17).
Time frame: 12 weeks
Response rate
Reduction of 50% or more in HRSD score from baseline to week 12
Time frame: 12 weeks
Remission rate
Final HRSD score \< 8
Time frame: 12 weeks
Anxiety symptoms
Changes from baseline to week 12 in Generalized Anxiety Disorder scale (GAD-7)
Time frame: 12 weeks
Self-reported perception of quality of life
Changes from baseline to week 12 in World Health Organization Quality of Life Short Version (WHOQOL-BREF)
Time frame: 12 weeks
Clinician-rated illness severity
Changes from baseline to week 12 in Clinical Global Impression scale (CGI)
Time frame: 12 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2020 to primary completion in Jan 2025, 59 months.
Of 24 phase 3 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 59 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Minocycline
Depressive Disorder, Treatment-Resistant →
Centre for Addiction and Mental Health →